Publication Name	World Journal of Pharmacology
Manuscript ID	15659
Country	United Kingdom

Received	2014-12-02 08:41
Peer-Review Started	2014-12-02 10:32
To Make the First Decision	2015-02-07 14:52
Return for Revision	2015-02-10 13:48
Revised	2015-02-22 03:23
Second Decision	2015-04-01 15:24
Accepted by Journal Editor-in-Chief	2015-04-01 18:12
Accepted by Executive Editor-in-Chief	2015-04-14 16:05
Articles in Press	2015-04-14 16:06
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-06-01 16:00
Publish the Manuscript Online	2015-06-19 15:32

ISSN	2220-3192 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Review
Article Title	Progress in pancreatic cancer therapeutics: The potential to exploit molecular targets
Manuscript Source	Invited Manuscript
All Author List	Kiruthikah Thillai, Debashis Sarker and Paul Ross
Funding Agency and Grant Number
Corresponding Author	Dr. Paul Ross, Department of Medical Oncology, Guy’s and St Thomas NHS Trust, Great Maze Pond, SE19RT London, United Kingdom. paul.ross@gstt.nhs.uk
Key Words	Pancreatic cancer; Adenocarcinoma; Targ­eted therapy; Genomics; Stroma; KRAS; Chemo­therapy
Core Tip	Pancreatic ductal adenocarcinoma is a cancer with several significant genetic aberrations that have recently been identified by international research efforts. Despite these findings, standard therapy for advanced disease consists primarily of chemotherapy. In the last few years two new chemotherapy regimens, FOLFIRINOX and Gemcitabine/Nab-paclitaxel, have demonstrated survival benefits in large phase III trials resulting in a change to current practise. However, the advent of targeted treatments has not yet had a significant impact in this disease compared with other malignancies. Current research strategies include developing therapies directed towards the RAS-RAK-MEK pathway, PI3K-AKT-mTOR pathway, notch pathway and immunotherapies to name but a few, with several clinical trials underway. It is likely that the hetero-geneous nature of pancreatic cancer necessitates a more persona-lised approach to management with targeted treatment guided by predictive biomarkers.
Publish Date	2015-06-19 15:32
Citation	Thillai K, Sarker D, Ross P. Progress in pancreatic cancer therapeutics: The potential to exploit molecular targets. World J Pharmacol 2015; 4(2): 180-192
URL	http://www.wjgnet.com/2220-3192/full/v4/i2/180.htm
DOI	http://dx.doi.org/10.5497/wjp.v4.i2.180

Full Article (PDF)	WJP-4-180.pdf
Full Article (Word)	WJP-4-180.doc
Manuscript File	15659-Review.doc
Answering Reviewers	15659-Answering reviewers.pdf
Conflict-of-Interest Disclosure Form	15659-Conflict-of-interest statement.pdf
Copyright License Agreement	15659-Copyright assignment.pdf
Peer-review Report	15659-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	15659-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	15659-Scientific misconduct check.pdf
Scientific Editor Work List	15659-Scientific editor work list.pdf